Literature DB >> 12665628

The novel human MOST-1 (C8orf17) gene exhibits tissue specific expression, maps to chromosome 8q24.2, and is overexpressed/amplified in high grade cancers of the breast and prostate.

J M M Tan1, E P C Tock, V T K Chow.   

Abstract

AIMS: To elucidate genes that participate in the process of oncogenesis, primers based on the E6 genes of genital human papillomaviruses (HPVs) were used to amplify potential expressed sequence tags (ESTs) from the MOLT-4 T lymphoblastic leukaemia cell line.
METHODS: Using the polymerase chain reaction (PCR) with human papillomavirus E6 gene primers, an EST from the MOLT-4 T lymphoblastic leukaemia cell line was amplified. Via rapid amplification of cDNA ends (RACE) and cycle sequencing from MOLT-4 and fetal lung cDNA libraries, overlapping cDNAs of 2786 bp and 2054 bp of the corresponding novel human intronless gene designated MOST-1 (for MOLT-4 sequence tag-1) were characterised and assigned the symbol C8orf17 by the HUGO Nomenclature Committee.
RESULTS: Both cDNAs contained a potential open reading frame (ORF) of 297 bp incorporating a methionine codon with an ideal Kozak consensus sequence for translation initiation, and encoding a putative hydrophilic polypeptide of 99 amino acids. Although reverse transcription PCR (RT-PCR) demonstrated MOST-1 expression in all 19 cancer and two normal cell lines tested, differential expression was seen in only nine of 16 normal tissues tested (heart, kidney, liver, pancreas, small intestine, ovary, testis, prostate, and thymus). A 388 bp fragment was amplified from the NS-1 mouse myeloma cell line, the sequence of which was identical to that within the MOST-1 ORF. The MOST-1 gene was mapped by fluorescent in situ hybridisation to chromosome 8q24.2, a region amplified in many breast cancers and prostate cancers, which is also the candidate site of potential oncogene(s) other than c-myc located at 8q24.1. Analysis of paired biopsies of invasive ductal breast cancer and adjacent normal tissue by semiquantitative and real time RT-PCR revealed average tumour to normal ratios of MOST-1 expression that were two times greater in grade 3 cancers than in grade 1 and 2 cancers. Quantitative real time PCR of archival prostatic biopsies displayed MOST-1 DNA values that were 9.9, 7.5, 4.2, and 1.4 times higher in high grade carcinomas, intermediate grade carcinomas, low grade carcinomas, and benign hyperplasias, respectively, than in normal samples.
CONCLUSIONS: These data suggest a role for MOST-1 in cellular differentiation, proliferation, and carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665628      PMCID: PMC1187302          DOI: 10.1136/mp.56.2.109

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  43 in total

1.  Identification of multiple genital HPV types and sequence variants by consensus and nested type-specific PCR coupled with cycle sequencing.

Authors:  V T Chow; E Loh; W M Yeo; S Y Tan; R Chan
Journal:  Pathology       Date:  2000-08       Impact factor: 5.306

Review 2.  The human papillomavirus E6 protein and its contribution to malignant progression.

Authors:  F Mantovani; L Banks
Journal:  Oncogene       Date:  2001-11-26       Impact factor: 9.867

3.  Complete nucleotide sequence, genomic organization and phylogenetic analysis of a novel genital human papillomavirus type, HLT7474-S.

Authors:  Vincent T K Chow; Peter W F Leong
Journal:  J Gen Virol       Date:  1999-11       Impact factor: 3.891

4.  Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer.

Authors:  O Saramäki; N Willi; O Bratt; T C Gasser; P Koivisto; N N Nupponen; L Bubendorf; T Visakorpi
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 5.  The Cancer Genome Anatomy Project: new resources for reading the molecular signatures of cancer.

Authors:  R L Strausberg
Journal:  J Pathol       Date:  2001-09       Impact factor: 7.996

6.  PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.

Authors:  L L Xu; B G Stackhouse; K Florence; W Zhang; N Shanmugam; I A Sesterhenn; Z Zou; V Srikantan; M Augustus; V Roschke; K Carter; D G McLeod; J W Moul; D Soppett; S Srivastava
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

7.  Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma.

Authors:  R Jin; B H Bay; V T Chow; P H Tan
Journal:  Breast Cancer Res Treat       Date:  2001-04       Impact factor: 4.872

8.  A draft annotation and overview of the human genome.

Authors:  F A Wright; W J Lemon; W D Zhao; R Sears; D Zhuo; J P Wang; H Y Yang; T Baer; D Stredney; J Spitzner; A Stutz; R Krahe; B Yuan
Journal:  Genome Biol       Date:  2001-07-04       Impact factor: 13.583

9.  Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer.

Authors:  R Jin; B H Bay; V T Chow; P H Tan; V C Lin
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

View more
  1 in total

1.  Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus.

Authors:  Christiane Robbins; Jada Benn Torres; Stanley Hooker; Carolina Bonilla; Wenndy Hernandez; Angela Candreva; Chiledum Ahaghotu; Rick Kittles; John Carpten
Journal:  Genome Res       Date:  2007-10-31       Impact factor: 9.043

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.